Identification of JAK Inhibitors as Potential Therapeutics for Inflammatory Bowel Disease Using Human Primary Cell 3D Models of Crohn’s Disease and Ulcerative Colitis

Dudum R, Payton O, Toohey C, et al. Digestive Disease Week 2025, Abstract No. Tu2040

Development of a Multicellular 3D Intestinal Model Using Human Primary Cells to Identify Novel IBD Therapies

Gervacio S, Dudum R, Aidnick H, et al. Digestive Disease Week 2025, Abstract No. Tu2035

Clinically Benchmarked Multi-Endpoint 3D Liver Spheroid NAM for DILI Prediction and SAR Prioritization 

Rachel Dudum, Mehrsa Mehrabi, Payton Olson, Cole Toohey, Haylee Aidnik, Caridad Rosette, Keith Murphy, Amar A. Sethi

Human 3D Liver Spheroid NAM for ADC DILI Risk Assessment 

Mehrsa Mehrabi, Payton Olson, Cole Toohey, Rachel Dudum, Haylee Aidnik, Caridad Rosette, Keith Murhpy, Amar A. Sethi

A Machine-Learning Enhanced Human Intestinal NAM for Diarrhea Risk Assessment Across Small Molecules and ADCs  

Vivian (Xiao) Han, Haylee Aidnik, Sherwin Gervacio, Cole Toohey, Caridad Rosette, Keith Murphy, Amar A. Sethi

Multicellular Human 3D Liver NAM for DILI Risk Assessment Across Small Molecules and Antibody Drug Conjugates 

Caridad Rosette, Mehrsa Mehrabi, Rachel Dudum, Payton Olson, Cole Toohey, Haylee Aidnik, Philip Tan, Keith Murphy, Amar A. Sethi

Multicellular Human Intestinal NAM for Diarrhea Risk Stratification Across Small Molecules and Antibody Drug Conjugates

Caridad Rosette, Vivian Xiao Han, Sherwin Gervacio, Cole Toohey, Haylee Aidnik, Keith Murphy, Amar A. Sethi

NAMkind™ Liver & Intestine Toxicity Prediction Across Small Molecules and Antibody Drug Conjugates 

Amar A. Sethi, Mehrsa Mehrabi, Vivian Xiao Han, Rachel Dudum, Sherwin Gervacio, Payton Olson, Cole Toohey, Haylee Aidnik, Philip Tan, Caridad Rosette, and Keith Murphy

NAMkind™ Client Study Report

Sample Report

Identify GI risk. Advance with insight.

Brochure

Identify liver risk. Advance with insight.

Brochure

Does your MASH therapy deliver?

Brochure